
Cytek Biosciences expands European footprint with new headquarters in Amsterdam’s Life Sciences District
Cytek expands to a new location in Amsterdam’s Life Sciences District
The California-based firm, a leader in spectral flow cytometry, has relocated its European operations to a new facility in Amsterdam’s Life Sciences District, an area increasingly attracting cutting-edge biotech and medical technology firms. The site includes offices, warehouse space, and a new customer training centre, increasing Cytek’s European footprint by more than 40 per cent.
The facility’s Training Centre offers a fully equipped laboratory environment where researchers can gain hands-on experience with Cytek’s instruments, particularly those built around its patented Full Spectrum Profiling™ (FSP®) technology. This immersive set-up enables scientists to unlock richer, high-dimensional cell data and enhance efficiency in research workflows.
According to the company, the expansion has been driven by strong growth in its reagents business, a key pillar of Cytek’s global innovation strategy. By bringing its warehouse operations in-house, Cytek aims to strengthen quality control, streamline logistics, and improve delivery reliability across Europe and beyond.
More international companies are calling Amsterdam home

With its strategic location and advanced life sciences ecosystem, Amsterdam continues to grow as a leading hub for biomedical innovation and research in Europe. A growing list of international companies, including Oracle, MotherDuck, and Delta Electronics, are choosing the Netherlands as a base for European operations and R&D investment.
The expansion is also expected to support the city’s ambitions under the Amsterdam Life Sciences & Health Strategy, which promotes collaborative innovation across academia, industry, and healthcare institutions to advance personalised medicine and diagnostics.
Related articles

Datamonk raises €1.6M to clean up medical imaging data with agentic AI

New research and diagnostics centre ADORE opens in Amsterdam

Amsterdam UMC leads €12 million lung cancer research project

Amsterdam’s LUMICKS lands €20M to revolutionise cancer drug discovery

Ellogon.AI secures €1M to advance immunotherapy innovation

Amsterdam’s ADORE Secures €9M to tackle cancer and neurodegenerative diseases

Global healthcare leaders embrace generative AI to close ‘critical gap’ says Philips report

€22M investment to help develop new therapies for blindness

HealthSage AI boosts healthcare AI with €3M investment

